Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

INO 4885

Next Previous
X
Search
Drug Profile

INO 4885

Alternative Names: INO-4885; WW-85

Latest Information Update: 09 Jan 2018

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Inotek Pharmaceuticals
  • Class Metalloporphyrins
  • Mechanism of Action Reactive oxygen species inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Kidney disorders

Highest Development Phases

  • Discontinued Asthma; Kidney disorders; Radiation injuries

Most Recent Events

  • 04 Jan 2018 Rocket Pharmaceuticals merged with Inotek Pharmaceuticals and the combined company was named Rocket Pharmaceuticals
  • 16 Sep 2010 INO 4885 is available for licensing. www.inotekcorp.com
  • 20 Jun 2008 INO 4885 is still in phase I safety trials for contrast induced nephropathy in USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top